Page last updated: 2024-12-11

sdz glc 756

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

SDZ GLC 756: a novel octahydrobenzoquinoline [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9840900
SCHEMBL ID14392424
MeSH IDM0269152

Synonyms (9)

Synonym
PDSP2_000837
PDSP1_000850
bdbm85047
sdz glc 756
SCHEMBL14392424
149328-94-9
(3r,4ar,10ar)-1-methyl-3-(pyridin-2-ylsulfanylmethyl)-3,4,4a,5,10,10a-hexahydro-2h-benzo[g]quinolin-6-ol
(3r,4ar,10ar)-1-methyl-3-((pyridin-2-ylthio)methyl)-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-ol
PD129364
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's6 (54.55)18.2507
2000's5 (45.45)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (14.29%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (85.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]